MedTrace Logo

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

NCT00184028 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-05-22

Study results available
· View outcomes & findings →

Summary

This research study is for subjects with squamous cell cancer of the head and neck which is not solely treatable with surgery or radiation. This research study involves treatment with an experimental chemotherapy combination of oxaliplatin and Taxotere. Tha main purpose of this study is to assess the effectiveness of this combination of medications for this type of cancer.

Approximately 54 subjects will take part in this study.

Conditions

  • Carcinoma of the Head and Neck

Interventions

DRUG

Taxotere

Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.

DRUG

Oxaliplatin

Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Principal Investigators

  • Barbara Gitlitz, MD · University of Southern California

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2009-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00184028 on ClinicalTrials.gov